Article info

Download PDFPDF

Original research
An open-label, phase II multicohort study of an oral hypomethylating agent CC-486 and durvalumab in advanced solid tumors

Authors

  1. Correspondence to Dr Daniel D De Carvalho; ddecarv{at}uhnresearch.ca; Dr Lillian L Siu; lillian.siu{at}uhn.ca
View Full Text

Citation

Taylor K, Loo Yau H, Chakravarthy A, et al
An open-label, phase II multicohort study of an oral hypomethylating agent CC-486 and durvalumab in advanced solid tumors

Publication history

  • Accepted June 23, 2020
  • First published August 4, 2020.
Online issue publication 
August 04, 2020

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.